Kairos Pharma, Ltd. (KAPA) vs NuCana PLC Sponsored ADR (NCNA)

Kairos Pharma, Ltd. and NuCana PLC Sponsored ADR are both Biotechnology companies. Kairos Pharma, Ltd. and NuCana PLC Sponsored ADR are of similar size ($6.1M and $5.7M). Across the 9 metrics below, NuCana PLC Sponsored ADR leads on 5 and Kairos Pharma, Ltd. on 4.

Valuation

Metric KAPA NCNA Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 1.26 0.00 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 1.45 0.74
EV/Sales n/m n/m 10.73
Earnings yield (113.92%) (175,037.66%) (28.84%)
Free cash flow yield (75.40%) (131,687.13%) (23.03%)

Profitability

Metric KAPA NCNA Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) (68.70%) (57.72%)
Return on assets (104.32%) (45.24%) (49.22%)
Return on invested capital (322.91%) (1,130.23%) 0.00%

Growth

Metric KAPA NCNA Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (30.44%) 98.96% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA NCNA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.98 4.73 4.73
Net debt to EBITDA 1.65 1.23 0.96

Dividend

Metric KAPA NCNA Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric KAPA NCNA Biotechnology median
Market cap 6.13m 5.69m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack